NovaBridge Biosciences (NBP) — Strategic Asset Allocation Index
NovaBridge Biosciences (NBP) has a Strategic Asset Allocation Index of 2.2% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $40.32 Million) total $40.32 Million, measured against net assets of $1.84 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
NovaBridge Biosciences Strategic Asset Allocation Index (2021–2024)
This chart shows how NovaBridge Biosciences's Strategic Asset Allocation Index has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the index stands at 2.2%, representing strategic assets of $40.32 Million against net assets of $1.84 Billion USD. Explore how efficiently does NovaBridge Biosciences generate cash to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for NovaBridge Biosciences (2021–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for NovaBridge Biosciences from 2021 to 2024, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is NovaBridge Biosciences worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 15.3% | $30.82 Million | $- | $30.82 Million | $201.16 Million | ▲ +15.3 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $1.72 Billion | ▼ -0.1 pp |
| 2022 | 0.1% | $4.47 Million | $- | $4.47 Million | $3.01 Billion | ▼ -1.1 pp |
| 2021 | 1.2% | $55.24 Million | $- | $55.24 Million | $4.59 Billion | — |